Captopril in low dose associated with octreotide in hepatorenal syndrome: A randomized study

Chelarescu, D.; Chelarescu, O.; Crumpei, Felicia; Stratan, I

doi:10.1016/s0168-8278(03)80588-3

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, adding some medication to the standard of volume expansion with albumin and vasoconstriction with midodrine/octreotide in treating HRS is recommended, including PTX and captopril 41 44 48. Another study concluded that removing albumin-bound substances with the MARS method can contribute to treating type I HRS 42…”

Section: Discussionmentioning

confidence: 99%

Management of hepatorenal syndrome and associated outcomes: a systematic review

Roozbeh,

Ezzatzadegan Jahromi,

Rezazadeh

et al. 2024

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundHepatorenal syndrome (HRS), a multiorgan condition of acute kidney injury, is seen in advanced liver disease. This study aims to evaluate the current treatment for HRS.MethodsThe authors searched PubMed, Scopus and Google Scholar literature. After quality assessment, 31 studies were included in this review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology and the population, intervention, comparison and outcome scheme were used. We included human-controlled trials that evaluate the current treatment for HRS. Two authors independently screened articles for inclusion, extracted data and assessed the quality of included studies.ResultsThis study investigated the studies conducted on the effects of different treatments on follow-up of HRS patients. We gathered 440 articles, so 31 articles remained in our study. Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine/octreotide, norepinephrine, etc) that showed the higher rate of HRS reversal was detected for terlipressin in 17 studies (10 of them were significant), 2 studies achieved an insignificant lower rate of the model for end-stage liver disease score for terlipressin, 15 studies showed a decreased mortality rate in the terlipressin group (4 of them were significant).ConclusionThis review showed that terlipressin has a significantly higher reversal rate of HRS than the other treatments. Even the results showed that terlipressin is more efficient than midodrine/octreotide and norepinephrine as a previous medication, in reverse HRS, increasing patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%